The serine/threonine protein phosphatase 2A controls autoimmunity

Amir Sharabi a,b,⁎, Isaac R. Kasper a, George C. Tsokos a

a Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States
b Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

A R T I C L E   I N F O
Article history:
Received 13 July 2017
Accepted with revision 19 July 2017
Available online xxxx

A B S T R A C T
Protein phosphatase 2A (PP2A) is the first serine/threonine phosphatase recognized to contribute to human and murine lupus immunopathology. PP2A expression in SLE is controlled both epigenetically and genetically, and it is increased in patients with SLE, which contributes to decreased IL-2 production, decreased CD3ζ, and increased FcRγ expression on the surface of T cells, increased CREM expression, hypomethylation of genes associated with SLE pathogenesis, and increased IL-17 production. A regulatory subunit of PP2A regulates IL-2 deprivation-induced T cell death and is decreased in SLE patients. A mouse overexpressing PP2A in T cells displays peripheral granulocytosis, elevated IL-17 production, and develops glomerulonephritis when challenged. A mouse which lacks PP2A, only in regulatory T cells develops severe autoimmunity and multiorgan inflammation because of loss of restraint on mTORC1 and inability of Foxp3+ cells to regulate conventional T cells. Targeting PP2A in T cell subsets may be therapeutic for SLE and other autoimmune diseases.

© 2017 Published by Elsevier Inc.

1. Introduction

Protein phosphatase 2A (PP2A) is a highly conserved and ubiquitous serine/threonine phosphatase that is reviewed here. It is involved in essential cellular functions including cell cycle progression, cellular metabolism, migration and apoptosis [1]. PP2A is a heterotrimer composed of three distinct subunits — the scaffold A subunit (PP2AA), the regulatory B subunit (PP2AB) and the catalytic C subunit (PP2AC). The scaffold A subunit and the catalytic C subunit (PP2AA–PP2AC) forms the PP2A core enzyme that is responsible for dephosphorylation, and this catalytic core associates with one of the regulatory B subunits. In humans each PP2A subunit is located on separate chromosomes. The diversity in PP2A isoforms (PPP2R1A, Aα family; PPP2R5, Aβ family; PPP2CA, Cα family; PPP2CB, Cβ family; PPP2CC, Cγ family) and PP2AB has at least 17 different isoforms that are categorized into four families as B family (B55; gene symbol PPP2R3), B′ family (B56; gene symbol PPP2R5), B″ family (PR72/130; gene symbol PPP2R3), and Striatin family [2] (Fig. 1).

PP2A activity is controlled through post-translational modifications at its carboxy-terminal tail [3], wherein phosphorylation of the Tyr307 residue at the carboxy-terminal end of PP2A, results in the inactivation of PP2A. Further, inhibition of PP2A activity occurs when alpha 4 associates with PP2Ac [4]. When alpha 4 binds PP2Ac, it also prevents its degradation [5]. PP2A is involved in the development of cancer, neurodegenerative diseases and systemic lupus erythematosus (SLE) [6,7]. In the last decade PP2A has been the focus of our research while studying autoimmune diseases. This review will focus on the role of PP2A in the development of autoimmunity and specifically SLE. In addition, it will exemplify the potential of the PP2Aβ diversity of subunits to affect the evolution of pathogenic pathways that may cause autoimmune diseases.

2. PP2A is elevated in patients with SLE

The levels (mRNA and protein) of the catalytic subunit and activity of PP2A, is increased in T cells from SLE patients [8]. This heightened expression occurs regardless of the disease activity status or the treatment the patients received and therefore it is considered a disease-specific abnormality. The expression levels in T cells are determined both genetically and epigenetically.

A CpG motif in the proximal promotor is involved in the transcription of the PP2A [9], whereas a single nucleotide polymorphism (SNP) in the first exon was recognized in a GWAS study to confer susceptibility for SLE [10]. The SNP is located within the cis site for the transcription Ikaros, a transcriptional repressor [11] that suppresses PP2A expression by modulating chromatin modifications. After binding Ikaros recruits histone deacetylase HDAC1 which leads to suppression of PP2A transcription. The susceptibility allele binds Ikaros with lower avidity and therefore its repressive activity may be limited. In addition, peripheral blood mononuclear cells from SLE patients were shown to have reduced levels of Ikaros mRNA [12], yet it is likely that proteins/factors in addition to Ikaros are involved in the regulation of PP2A levels (Fig. 2).
3. PP2A suppresses IL-2 production

The high levels of PP2A, in T cells from SLE patients play a significant role in decreased IL-2 expression as IL-2 levels could be restored upon silencing of the mRNA expression of PP2A [8]. Normalization of IL-2 was shown to be mediated by elevating the levels of phosphorylated cAMP response element-binding (pCREB) protein, which enable its binding to the IL-2 and c-fos promoters. As a result, the activity of activator protein 1 (AP-1- c-fos/c-jun heterodimer) increases and the reduced production of IL-2 becomes normal.

PP2A controls the wiring of the CD3/TCR complex by controlling the expression of CD3ζ- and FcγR chains at the transcriptional level [13]. The increased PP2A activity results in aberrant signaling of the CD3 complex that contributes to the abnormal T cell function. CD3ζ- and FcγR chains are affected antithetically by the transcription factor Elf-1, and PP2A dephosphorylates Elf-1 (at Thr-231), yielding limited binding of Elf-1 to the CD3ζ and FcγR promoters. Consequently, the content of CD3ζ-chain is decreased and that of FcγR-chain is increased within the CD3 complex. This aberrant TCR-initiated signaling is not propagated through the normally used CD3ζ-chain but rather through the FcγR-chain and corroborates decreased production of IL-2 [14]. Replenishment of the CD3ζ-chain expression in SLE T cells also results in increased production of IL-2 [15] (Fig. 3). Notably, although the effect of PP2A is counterbalanced by PKC, in SLE T cells it probably remains unopposed through this pathway because the expression and activity of PKC were reported to be low [8].

Another pathway that mediates the reduction in IL-2 levels in SLE is through PP2A-driven dephosphorylation of the transcription factor specificity protein-1 (SP-1) at Ser59 [16]. Consequently, SP-1 binds strongly to the basic leucine zipper transcription factor cAMP-responsive element modulator (CREM)α. CREMα is abnormally increased in SLE T cells and it directly binds to IL-2 and T cell receptor ζ-chain promoters to suppress their transcription (Fig. 4).

4. PP2A and pathogenesis of SLE

The steadily enhanced levels of PP2A, in SLE T-cells mediate dephosphorylation of MEK and ERK upon T cell activation, which results in decreasing the enzyme activity of DNA methyltransferase (DNMT). Consequently, DNA hypomethylation becomes predominant and in SLE it is considered a characteristic feature [17]. Among the methylation-sensitive genes that are highly expressed is CD70 gene, whose protein product is expressed on SLE-T cells and it is a costimulatory ligand for B cells thereby mechanistically participating in immunoglobulin overproduction.

In addition to the human data, the study of PP2A in mice has significantly elaborated on mechanistic pathways in the pathogenesis of SLE. Microarray analyses demonstrated that the increased expression of PP2A in T cells enables the production of an array of proinflammatory effectors, molecules, including IL-17 [18]. PP2A, regulates the Il17 locus by enhancing histone 3 acetylation in T cells from both PP2A transgenic mice and patients with SLE, and it involved the activation of interferon regulatory factor 4.
5. PP2A and the control of autoimmunity

We found that regulatory T cells (Tregs) require PP2A for keeping their suppressive capabilities in vivo [19]. Mice whose Tregs are deficient in PP2A develop a severe lymphoproliferative and autoimmune disorder with spontaneous activation of the immune system and production of autoantibodies that were also against lupus-associated nuclear autoantigens. These mice manifest wasting, dermatitis, scaly tails and ears, skin rash and ulcerations, all of which showed similarities to the phenotype of scurfy mice [20]. Mice with PP2A-deficient Tregs had greater activation of both CD4+ T cells and CD8+ T cells and they produced significantly larger amounts of IL-17 and IL-2, IFN-γ, and TNF-α.

Potent Tregs maintain PP2A activity in contrast to conventional T cells (Tconv) wherein PP2Ac is inactivated by Tyr307-phosphorylation in response to TCR stimulation. Although both Tregs and Tconv have equal levels of SET that phosphorylates at Tyr307-[21], only Tregs had higher amounts of ceramide, which inhibits SET, thus allowing increased activity of PP2A in Tregs despite the high levels of SET. This difference between the two cell types is explained by the action of the Treg master gene Foxp3 that targets and represses Sgms1 encoding the enzyme catalyzing ceramide, eventually leading to ceramide accumulation in Tregs. Ceramide-driven activation of PP2Ac in Tregs restrains the mTORC1 complex (Fig. 5).

6. PP2A B subunits

The PP2A family of phosphatases comprises about 100 heterotrimeric holoenzymes. It is achieved due to the combinatorial association between the different subunits that compose PP2A. The regulatory PP2A B subunit families are composed of 4 with up to 58 family members that have been identified, resulting in a large diversity of PP2A holoenzymes [22]. The regulatory subunits confer substrate specificity and subcellular localization. The PP2A trimer is assembled when the PP2A core enzyme (the A and C dimer) gets associate with the appropriate B subunit, after which the specificity and regulation of PP2A is then determined [23]. In the literature most of the B subunits are described in relation to cancer and only a few of them are linked to autoimmune diseases.

6.1. B subunit - B55 alpha (PPP2R2A)

B55 alpha isoform was shown to affect cell cycle and stress survival protein. In cancer cells it affected apoptosis through survival signaling conveyed by dephosphorylation of AKT at threonine 308 [24], and it was also capable to affect PKC alpha [25]. Thus, B55 alpha is likely to share some of these pathways in autoreactive cells to affect their survival and proliferative status. In the context of autoimmunity, the B55α-PP2Aα complex was demonstrated to control autophagy [26]. Autophagy is induced following the formation of autophagy-related proteins that produce complexes such as ULK1 [27]. The latter was found to have at least two mTOR sites and during amino acid starvation of the cells when autophagy is initiated, these sites are dephosphorylated by PP2Aα–B55α. In SLE it is suggested that autophagy may play a pathogenic role. B55α was shown in patients and in lupus-prone mice to regulate the survival of autoreactive B cells and to promote differentiation of plasma cells [28]. Further, autophagy-related gene 5 (ATG5) was linked to SLE in genome-wide association studies [29,30].

6.2. B subunit - B55 beta (PPP2R2B)

PP2A supports the survival of autoreactive T cells. In healthy subjects, the B5 subunit of PP2A (e.g. PPP2R2B) mediates apoptosis of resting T cells that is due to IL-2 deprivation [31]. Activated T cells are protected from apoptosis, however, as IL-2 declines it leads to the induction of PPP2R2B and then the cells are no longer protected from apoptosis. In patients with SLE, the expected induction of PP2A B5 in T cells upon IL-2 deprivation did not occur in 50% of the patients, and indeed this defect was accompanied by the cell resistance to apoptosis, which might accounted, at least in part, for the longer survival of autoreactive T cells.

6.3. B′ subunit – B56γ - (PPP2R5C)

The PP2A regulatory subunit B56 was reported as suppressor of NFκB in TCR signaling [32]. NFκB is essential for activation of normal T cells [33]. Human T cells that were stimulated via their TCR had increased the expression of B56. Silencing of B56 led to increased IKK and IκB phosphorylation, enhanced NFκB activity, which resulted in increased NFκB target gene expression, including IL-2 that was strongly enhanced on mRNA and protein levels. Moreover, T cell proliferation was increased upon B56 silencing.

6.4. B″ subunit – PR130 - (PPP2R3A)

The regulatory B subunit PR130 of the PP2A is the ubiquitous spliced variant of the PPP2R3A gene (PR72 is another spliced variant of this gene).

![Fig. 5.](http://dx.doi.org/10.1016/j.clim.2017.07.012)
gene). The biological function of PP2A-PR130 complex was demonstrated to affect EGFR degradation and EGF-mediated signaling [34]. PR130 interacts with SHIP2 and prevents EGF-induced EGFR degradation, thereby constituting a positive regulator of EGF signaling.

EGFR signaling regulates lipocalin 2 (LCN-2) that is a biomarker for renal injury including in lupus nephritis [35]. Polymorphism of the EGFR Brs I gene was related to SLE [36]. Further, autoantibodies to the recombiant extracellular domain of EGFR were detected in sera from lupus prone mice in patients with scleroderma and SLE [37]. Given that PR130-PP2A complex controls EGFR degradation it is possible that it may play a pathogenic role in the development of these autoantibodies.

7. Concluding remarks

Tyrosine phosphatases have been implicated in the expression of autoimmunity [38]. Ser/Thr phosphatases however, have not been considered in the pathogenesis of autoimmunity. The work which was discussed here presents the role of PP2A in the regulation of signaling pathways in SLE T cells and assigns to it a central role. Study of PP2A in genetically engineered mice has shown that PP2A may control opposite pathways in SLE T cells and assigns to it a central role. Study of PP2A is required in the pathogenesis of autoimmunity. The work which was

References

[8] M. Patel, S. Storrie, D. Keaney, M. Tsokos, Given that PR130-PP2A complex controls EGFR degradation it is possible that it may play a pathogenic role in the development of these autoantibodies.

Work was supported by NIH grants RO1 AI68787 and T32 74549 to CCT.


